Immunocore Holdings (IMCR) Operating Margin (2023 - 2026)

Immunocore Holdings has disclosed Operating Margin across 4 years of filings, most recently posting 6.82% for Q1 2026.

• Operating Margin for Q1 2026 came in at 6.82%, up 1068.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 8.35% (up 592.0% YoY), and the FY2025 annual result was 11.34%, up 1138.0% from the prior year.
• Operating Margin came in at 6.82% for Q1 2026 at Immunocore Holdings, up from 18.85% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 6.82% in Q1 2026 to a low of 37.57% in Q1 2024.
• The 4-year median for Operating Margin is 21.24% (2024), against an average of 17.43%.
• Across the five-year window, Operating Margin tumbled 1069 bps in 2024 and jumped 3372 bps in 2025, its largest moves.
• Immunocore Holdings' Operating Margin stood at 24.3% in 2023, then rose by 5 bps to 23.14% in 2024, then gained by 19 bps to 18.85% in 2025, then surged by 136 bps to 6.82% in 2026.
• The last three Operating Margin figures came in at 6.82% (Q1 2026), 18.85% (Q4 2025), and 6.92% (Q3 2025), per Business Quant data.